Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-19: Adagrasib + nab-Sirolimus in KRAS G12C Solid Tumors
NCT05840510Phase 1Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib and sirolimus in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Primary endpoints: Safety and tolerability in the study population at 30 months, Maximum Tolerated Dose at 30 months and 2 more. Started Aug 2023; status: terminated.
02
Drugs
adagrasibsirolimus
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05840510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840510.